Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imaging and Biomarkers in Cardiac AL Amyloidosis
NCT04392960Completed
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Jul 2020
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of florbetaben in amyloid light chain amyloidosis, sponsored by IRCCS San Matteo Foundation. Primary endpoints: Evaluation of the prognostic relevance of advanced imaging variables at 12 months and Evaluation of advanced imaging variables in response assessment at 6 months. Started Jul 2020; status: completed.
02
Drugs
florbetaben
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT04392960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04392960.